BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 19876546)

  • 1. Intellectual property and access to medicines: an analysis of legislation in Central America.
    Cerón A; Godoy AS
    Bull World Health Organ; 2009 Oct; 87(10):787-93. PubMed ID: 19876546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trade-Related Aspects of Intellectual Property Rights Flexibilities and Public Health: Implementation of Compulsory Licensing Provisions into National Patent Legislation.
    McGIVERN L
    Milbank Q; 2023 Dec; 101(4):1280-1303. PubMed ID: 37646392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Has the implementation of the TRIPS Agreement in Latin America and the Caribbean produced intellectual property legislation that favours public health?
    Oliveira MA; Bermudez JA; Chaves GC; Velásquez G
    Bull World Health Organ; 2004 Nov; 82(11):815-21. PubMed ID: 15640916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of intellectual property rights on access to medicines in the WHO African region: 25 years after the TRIPS agreement.
    Motari M; Nikiema JB; Kasilo OMJ; Kniazkov S; Loua A; Sougou A; Tumusiime P
    BMC Public Health; 2021 Mar; 21(1):490. PubMed ID: 33706726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impacts of intellectual property provisions in trade treaties on access to medicine in low and middle income countries: a systematic review.
    Islam MD; Kaplan WA; Trachtenberg D; Thrasher R; Gallagher KP; Wirtz VJ
    Global Health; 2019 Dec; 15(1):88. PubMed ID: 31888688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Public health-oriented intellectual property and trade policies in Africa and the regional mechanism under Trade-Related Aspects of Intellectual Property Rights amendment.
    Adekola TA
    Public Health; 2019 Aug; 173():1-4. PubMed ID: 31203136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benchmarking progress in tackling the challenges of intellectual property, and access to medicines in developing countries.
    Musungu SF
    Bull World Health Organ; 2006 May; 84(5):366-70. PubMed ID: 16710545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Evolution of the international intellectual property rights system: patent protection for the pharmaceutical industry and access to medicines].
    Chaves GC; Oliveira MA; Hasenclever L; de Melo LM
    Cad Saude Publica; 2007 Feb; 23(2):257-67. PubMed ID: 17221075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Essential medicines and the TRIPS Agreement: collision between the right to health and intellectual property rights].
    Allard Soto R
    Salud Colect; 2015 Mar; 11(1):9-21. PubMed ID: 25853827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implications of the Central America-Dominican Republic-Free Trade Agreement for the nutrition transition in Central America.
    Hawkes C; Thow AM
    Rev Panam Salud Publica; 2008 Nov; 24(5):345-60. PubMed ID: 19141177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A trade agreement's impact on access to generic drugs.
    Shaffer ER; Brenner JE
    Health Aff (Millwood); 2009; 28(5):w957-68. PubMed ID: 19706626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Affordable antiretroviral drugs for the under-served markets: how to expand equitable access against the backdrop of challenging scenarios?
    Dionisio D; Cao Y; Hongzhou L; Kraisintu K; Messeri D
    Curr HIV Res; 2006 Jan; 4(1):3-20. PubMed ID: 16454707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TRIPS-plus and access to medicines in China.
    Chen J; Nie X; Yao P; Shi L
    J Public Health Policy; 2013 May; 34(2):226-38. PubMed ID: 23552834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [International experience in the legal regulation of the circulation of medicines through the prism of the law of the world trade organization].
    Pasechnyk OV; Hendel NV
    Wiad Lek; 2018; 71(3 pt 2):772-776. PubMed ID: 29783265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analyzing the impact of trade and investment agreements on pharmaceutical policy: provisions, pathways and potential impacts.
    Gleeson D; Lexchin J; Labonté R; Townsend B; Gagnon MA; Kohler J; Forman L; Shadlen KC
    Global Health; 2019 Nov; 15(Suppl 1):78. PubMed ID: 31775767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Access to generic antiretrovirals: inequality, intellectual property law, and international trade agreements.
    Castro A; Westerhaus M
    Cad Saude Publica; 2007; 23 Suppl 1():S85-96. PubMed ID: 17308722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Regional Comprehensive Economic Partnership, Intellectual Property Protection, and Access to Medicines.
    Townsend B; Gleeson D; Lopert R
    Asia Pac J Public Health; 2016 Nov; 28(8):682-693. PubMed ID: 27920239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The ethics of intellectual property rights in an era of globalization.
    Shah AK; Warsh J; Kesselheim AS
    J Law Med Ethics; 2013; 41(4):841-51, Table of Contents. PubMed ID: 24446942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Canada and access to medicines in developing countries: intellectual property rights first.
    Lexchin J
    Global Health; 2013 Sep; 9():42. PubMed ID: 24007595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Academic patents and access to medicines in developing countries.
    Sampat BN
    Am J Public Health; 2009 Jan; 99(1):9-17. PubMed ID: 19008514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.